8MV0 Stock Chart & Stats
€1.58
-€0.15(-8.67%)
At close: 4:00 PM EDT
€1.58
-€0.15(-8.67%)
Day’s Range― - ―
52-Week Range€1.51 - €10.80
Previous CloseN/A
Volume0.00
Average Volume (3M)454.00
Market Cap
€42.46M
Enterprise Value€95.63
Total Cash (Recent Filing)€19.17M
Total Debt (Recent Filing)€16.42M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Aug 11, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding22,667,843
10 Day Avg. Volume946
30 Day Avg. Volume454
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.75
Price to Sales (P/S)2.77
P/FCF Ratio-9.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.38Price Target Upside556.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.35
Revenue Forecast (FY)€37.71M
Bulls Say, Bears Say
Bulls Say
Proprietary Botanical‑synthesis CDMO MilestonesAdvancement through multi‑stage CDMO programs and retention of ownership stakes converts technical progress into potential royalty and manufacturing revenue streams. This reduces long‑term commercialization risk, differentiates the platform versus commodity suppliers, and creates durable upside if scale and repeat programs follow.
VINIA D2C Traction And Product AdoptionA large active user base and strong product ratings indicate durable customer engagement and repeat purchase potential for the D2C channel. Scalable direct revenue and customer data improve lifetime value and marketing efficiency long term, strengthening a predictable revenue leg complementary to CDMO work.
Improved Balance Sheet Leverage PositionA materially improved leverage profile and stronger equity base reduce short‑term financing distress risk and give management runway to execute capacity investments and commercial milestones. Better capital structure enhances ability to raise targeted capital and negotiate CDMO partnerships without immediate refinancing pressure.
Bears Say
Persistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow forces reliance on external funding or equity issuance, constraining capital allocation and increasing dilution or interest obligations. Until operating cash flow turns positive, growth investments and capacity expansion remain dependent on financing availability and cost.
Dependence On New Facility For Meaningful Capacity ScaleGrowth from high‑value CDMO programs and saffron/fragrance commercialization hinges on timely facility buildout. Delays or higher capital requirements would push out revenue conversion, increase per‑unit costs, and elevate execution and financing risk over the medium term, weakening the scalability case.
Early‑stage Technical And Commercialization Risk For Novel AssetsKey pipeline assets require further validation and process optimization; uncertain downstream processing costs and market fit mean potential revenue may be delayed or margin‑challenged. This elevates long‑term execution risk and could compress future profitability if scale efficiencies are not achieved.
BioHarvest Sciences News
8MV0 FAQ
What was BioHarvest Sciences’s price range in the past 12 months?
BioHarvest Sciences lowest stock price was €1.51 and its highest was €10.80 in the past 12 months.
What is BioHarvest Sciences’s market cap?
BioHarvest Sciences’s market cap is €42.46M.
When is BioHarvest Sciences’s upcoming earnings report date?
BioHarvest Sciences’s upcoming earnings report date is Aug 11, 2026 which is in 2 days.
How were BioHarvest Sciences’s earnings last quarter?
Currently, no data Available
Is BioHarvest Sciences overvalued?
According to Wall Street analysts BioHarvest Sciences’s price is currently Undervalued.
Does BioHarvest Sciences pay dividends?
BioHarvest Sciences does not currently pay dividends.
What is BioHarvest Sciences’s EPS estimate?
BioHarvest Sciences’s EPS estimate is -0.1.
How many shares outstanding does BioHarvest Sciences have?
BioHarvest Sciences has 22,667,843 shares outstanding.
What happened to BioHarvest Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioHarvest Sciences?
Currently, no hedge funds are holding shares in DE:8MV0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioHarvest Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€10.38 (556.92% Upside)
€10.38 (556.92% Upside)
Blogger Sentiment
Bullish
DE:8MV0 Sentiment 67%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
71.33%
Trailing 12-Months
Company Description
BioHarvest Sciences
BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.
8MV0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid technological and commercial progress — notable CDMO milestones (Stage 1 completions, a $1.2M Stage 2 fragrance contract with 20% retained ownership, and Saffron Stage 1 advancement), stronger cash position, and clear D2C product traction (VINIA Blood Flow Hydration, strong reviews, active users). However, near-term financials show continued net losses, increased operating and marketing spend, and a deliberate D2C marketing reset that temporarily depressed revenue. Execution risks remain around manufacturing capacity timing (new facility target H2 2027), potential future capital needs, and early-stage validation for novel assets. Overall the positives (milestones, cash build, pipeline, product traction and reiterated guidance) outweigh the short-term headwinds and uncertainties, but successful execution over the next quarters — especially H2 2026–2027 — will be critical to realize the opportunities.View all DE:8MV0 earnings summaries8MV0 Stock 12 Month Forecast
Average Price Target
€10.38
▲(556.92% Upside)